DeciBio have a great interactive Tableau dashboard which you can use to browse and filter their analysis of 97 â€œlaboratory biomarker analysisâ€ ImmunOncolgy clinical trials; see: Diagnostic Biomarkers for Cancer Immunotherapy â€“ Moving Beyond PD-L1. The raw data comes from ClinicalTrials.gov where you can specify a “ctDNA” search and get back 50 trials, 40 of which are open.
Two of these trails are happening in the UK. Investigators at The Royal Marsden are looking to measure the presence or absence of ctDNA post CRT in EMVI-positive rectal cancer. And Astra Zeneca are looking for ctDNA as a secondary outcome to obtain a preliminary assessment of safety and efficacy of AZD0156 and its activity in tumours by evaluation of the total amount of ctDNA.
You can also specify your own search terms and get back lists of trials from OpenTrials which went live very recently. The Marsden’s ctDNA trials above is currently listed.
You can use the DeciBio dashboard on their site. In the example below I filtered for trials using ctDNA analysis and came up with 7 results:
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
- Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
- Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors
- Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
- Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
- Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer
- Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib
Thanks to DecBio’s Andrew Aijian for the analysis, dashboard and commentary. And to OpenTrials for making this kind of data open and accessible.